Clinical Trial Update: To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

This update covers a completed Phase 1/2 clinical trial evaluating Tinengotinib (TT-00420) as both monotherapy and in combination therapy for multiple advanced …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Breast Cancer
• Cholangiocarcinoma
• Gastric Cancer
• Prostate Cancer
• Small Cell Lung Cancer
• Thyroid Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Tinengotinib (tinengotinib)

Snippet

Sponsor: TransThera Sciences (Nanjing), Inc. | Conditions: Advanced Solid Tumor, Cholangiocarcinoma | Phase 1, Phase 2 | Status: COMPLETED